Clinical trial Recruiting at 1 site Interventional Ages 18 and up Women only

Investigating complex congenital heart defects in fetuses using multi-omics techniques

Official title: Antenatal Investigation of Fetuses With Complex Congenital Heart Defects Using multiOMICS

Run by University Hospital, Bordeaux · NCT06705543 · Data updated 2026-11-12

This study is trying to find out what causes complex heart defects in unborn babies by looking at their genetic and environmental factors using samples from amniotic fluid.

Quick facts

Study typeInterventional
Ages18 Years and up
SexWomen only
Enrollment40 (estimated)
SponsorUniversity Hospital, Bordeaux
Academic / other
Locations2 sites (Bordeaux and 1 other locations)
StatusRecruiting
StartedApril 1, 2025
Main results expectedJune 2026
Study endsDecember 2026
Registry record updatedApril 10, 2025
Trial IDNCT06705543 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates for this study are pregnant women aged 18 and older carrying a single fetus diagnosed with a complex non-syndromic congenital heart defect, without identified chromosomal abnormalities.

Probably not a fit

Patients with syndromic congenital heart defects or those whose fetuses have identified chromosomal abnormalities or infections may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to explore the underlying causes of complex congenital heart defects (CHD) in fetuses by employing a multi-omics approach, which includes exome sequencing, RNA sequencing, and methylation analysis. The research focuses on identifying epigenetic factors that may contribute to these cardiac malformations, particularly in relation to environmental influences during pregnancy. By analyzing amniotic fluid samples, the study seeks to uncover the complex interplay between genetic and environmental factors that lead to CHD. The findings could enhance our understanding of the etiology of these defects and improve prenatal diagnostics.

Why it matters

Potential benefit: If successful, this study could lead to better identification of risk factors for congenital heart defects, potentially improving prenatal care and outcomes for affected fetuses.

How similar studies have gone: While the multi-omics approach is gaining traction, this specific application to complex congenital heart defects is relatively novel and has not been extensively tested in prior studies.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

Fetuses with congenital heart disease :

* Pregnant women aged 18 and more
* Single foetal pregnancy in which the foetus has a complex non-syndromic congenital heart defect, with no identified chromosomal abnormality, gene syndrome or infection.
* Patient for whom the indication for amniocentesis has been accepted by the CPDPN and accepted by the couple/patient
* Gestational age between 20 and 28 weeks' gestation.
* Person affiliated to or benefiting from a social security scheme.
* Free, informed and express consent (confirmed in writing) (at the latest on the day of inclusion and before any examination required by the research).

Control Population for RNAseq and MéthlySeq

* Pregnant women aged 18 and more
* Patient in whom the indication for amniocentesis has been retained by the CPDPN and accepted by the couple/patient, for a non-malformative ultrasound anomaly (hyperechoic bowel, idiopathic hydramnios, increased risk of trisomy 21, agenesis of the OPN, suspected toxoplasmosis/CMV seroconversion), with no chromosomal anomaly, gene syndrome or infection identified.
* Gestational age between 20 and 28 weeks' gestation.
* Person affiliated to or benefiting from a social security scheme.
* Free, informed and express consent (confirmed in writing) (at the latest on the day of inclusion and before any examination required by the research).

Exclusion Criteria:

For both populations (cases and controls) :

* Female minors,
* Patients not affiliated to the social security system,
* Patients who do not understand French,
* Patients under guardianship
* Multiple pregnancies, or where the foetus has associated malformations

Where it's running

  • CHU de Bordeaux
    Bordeaux, France
    Recruiting
  • CHU de Nantes
    Nantes, France
    Not yet recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.